WASHINGTON — Already grappling with divisions in his own country over vaccine mandates and questions about the ethics and efficacy of booster shots, President Biden is facing another front of discord: a split among world leaders over how to eradicate the coronavirus globally, as the highly infectious Delta variant leaves a trail of death in its wake.
At a virtual summit on Wednesday, while the annual United Nations General Assembly meeting is underway, Mr. Biden will try to persuade other vaccine-producing countries to balance their domestic needs with a renewed focus on manufacturing and distributing doses to poor nations in desperate need of them.
Covax, the United Nations-backed vaccine program, is so far behind schedule that not even 10 percent of the population in poor nations is fully vaccinated, experts said.
The push, which White House officials say seeks to inject urgency into vaccine diplomacy, will test Mr. Biden’s doctrine of furthering American interests by building global coalitions. Coming on the heels of the United States’ calamitous withdrawal from Afghanistan last month that drew condemnation from allies and adversaries alike, the effort to rally world leaders will be closely watched by public health experts and advocates who say Mr. Biden is not living up to his pledges to make the United States the “arsenal of vaccines” for the world.
“This is one of the most moral questions of our time,” Representative Rosa DeLauro, Democrat of Connecticut, said last week. “We cannot let the moment pass. And the United States can recapture its leadership role by taking on what is one of the greatest humanitarian causes ever — and we need to bring this pandemic to an end.”
The landscape is even more challenging now than when Covax was created in April 2020. Some nations in Asia have imposed tariffs and other trade restrictions on Covid-19 vaccines, slowing their delivery. India, home to the world’s largest vaccine maker, banned coronavirus vaccine exports. And an F.D.A. panel on Friday recommended Pfizer booster shots for those over 65 or at high risk of severe Covid, meaning that vaccine doses that could have gone to low and lower-middle income countries would remain in the United States.
“If somebody had told us that 20 months into this pandemic we would still be seeing rates of infection and loss of life of the magnitude we are, I think we would have been absolutely horrified,” said Peter Sands, executive director of the Global Fund, a founding partner in the global collaboration that created Covax.
“That should underscore a real sense of urgency, that when you’re fighting a pandemic, it doesn’t make sense to fight it slowly,” Mr. Sands said.
Officials said Wednesday’s summit would be the largest gathering of heads of state to address the coronavirus crisis. It aims to encourage pharmaceutical makers, philanthropists and nongovernmental organizations to work together toward vaccinating 70 percent of the world’s population by the time the U.N. General Assembly meets in September 2022, according to a draft document the White House sent to the summit participants.
“We also know this virus transcends borders,” Mr. Biden said on Sept. 9. “That’s why, even as we execute this plan at home, we need to continue fighting the virus overseas, continue to be the arsenal of vaccines.”
“That’s American leadership on a global stage,” he said.
Experts estimate that 11 billion doses are necessary to achieve widespread global immunity. The United States has pledged to donate more than 600 million — more than any other nation — and the Biden administration has taken steps to expand vaccine manufacturing in the United States, India and South Africa. The 27-nation European Union aims to export 700 million doses by the end of the year.
But as recently as July, only 37 percent of people in South America and 26 percent in Asia had received at least one vaccine shot, according to Rajiv J. Shah, the head of the U.S. Agency for International Development during the Obama administration. The figure stood at just 3 percent in Africa, Mr. Shah wrote in an essay published last month in Foreign Affairs.
An estimate by the ONE Campaign, which fights extreme poverty and preventable disease, showed that the leading seven developed nations would together be sitting on a surplus of more than 600 million vaccine doses by the end of 2021.
That is enough to fully vaccinate every adult in Africa, said Jenny Ottenhoff, ONE’s senior director for health policy.
Most doses that have been committed, however, will not be delivered to the needier nations, nor injected into arms, until next year. Given the sluggish distribution, said Dr. Kate O’Brien, the World Health Organization’s top vaccines expert, “we can see clearly from the data that’s coming out that we are very far” from vaccinating 70 percent of the world’s population by the middle of next year, as initially projected.
The president is also under intense pressure from global health advocates who say donating doses is not enough and want him to scale up manufacturing capacity overseas.
On Monday, the advocacy group Health Gap will stage a demonstration near the U.N. headquarters in New York calling on Mr. Biden to “end vaccine apartheid.” A coalition of nearly 60 human rights and other advocacy groups will also send Mr. Biden a letter urging him to back a $25 billion investment that would produce 8 billion doses within a year — and to ask Congress to include a specific line item for it in the $3.5 trillion “Build Back Better” budget legislation that lawmakers are now considering.
“We cannot ‘donate’ our way to safety,” they wrote.
That growing gap between the vaccine haves and the vaccine have-nots has led to a rift between wealthy countries and most of the rest of the world, one that has only deepened with the rampant spread of the Delta variant and potentially thousands of others that are on the rise. Several of the most virulent strains were first identified in lower-income countries, including South Africa and India — both of which have fully vaccinated only 13 percent of their populations.
More than 100 low-income countries are banking on Mr. Biden to lean on the European Union and Group of 7 states at the summit on Wednesday to agree to waive intellectual property rights to vaccine production so that they can be shared with manufacturers in other, developing nations. Some of the leading coronavirus vaccines are produced in Europe — including Pfizer-BioNTech in Germany and AstraZeneca in England — and officials there have been accused of putting potential profits ahead of beating back the pandemic.
The European Union again objected to a plan to waive the vaccine property rights at a closed-door World Trade Organization meeting last week in Geneva, according to a senior European diplomat familiar with the discussion.
The Biden administration has supported a waiver, although not as forcefully as its advocates want.
“The action by the U.S. is particularly important to shift things forward, and make people come around the table and discuss these issues,” said Zane Dangor, a special adviser to South Africa’s foreign minister. He said European Union officials “would like to kick this discussion further down the road.”
Understand Vaccine and Mask Mandates in the U.S.